

Vitamine D disorders

Vitamine D

-
- 7- DehydroCholesterol $\xleftrightarrow{\text{UV light}}$ Vitamine D₁
 - Vitamine D₂: Plant source
 - Vitamine D₃: Animal source
 - Vitamine D₂ n D₃....equally effective
 - 25(OH)D.the major circulating n storage form

Vitamine D metabolism



Vitamine D deficiency states

- Reduced Vit D

Intake....dietary inadequacy

Production....sun exposure

Absorption....malabsorption syndrome

- Excessive loss of Vit D

Catabolism....Phenytoin, R-cin, Barbiturates

Hepatobiliary circulation....small bowel ds
or resection

Vitamine D deficiency states

- Impaired metabolism
 - 25-hydroxylation: Liver ds, INH
 - 1 α -hydroxylation: CKD, Hypoparathyroidism
 - 1 α -hydroxylase mutations
 - X-linked hypophosphatemic rickets
 - Target organ resis: VDR mutations

Vitamine D deficiency

■ Clinical manifestations:

- Hypocalcemia, tetany, seizures
- Osteopenia, rickets, osteomalacia
- Proximal myopathy
- Pathologic bone fractures

■ Diagnosis:

- 25(OH)D (< 15 ng/mL)
- Raised S. PTH
- Low S. Ca, ↑ALP (bone-specific)
- X-ray...Osteopenia, Pseudofractures

■ Treatment:

- Therapeutic dose = 40,00 IU/d
- Prophylactic dose = 800 IU/d
- Various formulations n doses
 1. Clacitriol ($1,25(\text{OH})_2\text{D}_3$) = 0.25-0.5 $\mu\text{g}/\text{d}$
 2. Doxecalciferol ($1(\text{OH})\text{D}_2$) = 2.5-5.0 $\mu\text{g}/\text{d}$
 3. Calciferol (Vit D₂) = 50,000 IU wkly X 3 mth
f/b 800 IU/d
 4. Inj. Vit D = 2.5 MU deep i/m Biannually
 - ❖ Always add Ca with Vit D supplementation
 - ❖ Normocalcemia (<1 wk); ALP n PTH in 3-6 mth

Vit.D intoxication

1. Dietary Vit.D intoxication

- Chronic ingestion of Vit.D > 50,000 U/d
(upper limit of normal dietary intake = 2000)
- Δ : 25(OH)D > 100 ng/mL
- Treatment:
 - i. Stop Vit.D suppl n restrict dietary Ca
 - ii. Hydrocortisone < 100mg/d if \hat{S} . Ca > 4 wks
(* substantial fat stores of Vit D)

Vit.D intoxication

- 2. Chr granulomatous dr
 - Sarcoidosis, TB, Fungal infxns
 - Excess Vit.D synthesized by Macrophages
 $(25(\text{OH})\text{D} \rightarrow 1,25(\text{OH})_2\text{D})$
 - No negative feed-back from S. Ca or PTH
 - Treatment:
 - Treat underlying condition
 - Avoid sunlight exposure, limit dietary Ca n Vit.D; may use steroids

Parathyroid disorders

Parathyroid disorders

■ Hyperparathyroidism:

1. Pr. Hyperparathyroidism

Solitary adenoma (80%)

MEN 1 (Wermer's synd: Pitutary n Pancreas)

MEN 2A (Medullary Ca thyroid + Pheochromo)

MEN 2B (Multiple Neuromas + MCT + PCC)

2. Sec. → CKD, Lithium therapy

■ Familial hypocalciuric hypercalcemia

Pr. Hyperparathyroidism

■ Clinical features:

- i. Asymptomatic
- ii. Bone, Stone, Groan, Mone
- Bone → high turnover bone ds
 - Osteitis fibrosa cystica
 - X-ray: subperiosteal resorption
 - Histo: multinucleated osteocasts at bone surface pits
 - Formation/Resorption markers:
ALP, Procollagen/Collagen telopeptide

Pr. Hyperparathyroidism

- Stone → Nephrocalcinosis
→ Nephrolithiasis
- Groan → Refractory gastritis
→ Zollinger-Ellison syndrome
→ Pancreatitis
- Mone → Neuropsychiatric manifestations
→ Neuropathy, Parathyroid myopathy

Pr. Hyperparathyroidism

- Diagnosis: Hypercalcemia with ↑ S. PTH
- Treatment: Medical or Surgical ?
 - Medical → SERMs (Raloxifene)
 → Calcimimetics (CaSR +)
 - ❖ Annual S. Creat, DEXA scan n Biannual S. Ca

Pr. Hyperparathyroidism

➤ Surgery

- I. Severe hyperCa ($>15 \text{ mg\%}$)
or hypercalciuria ($>400 \text{ mg/d}$)
- II. Asymp hyperPTH with age $< 50 \text{ yrs}$
- III. T-score < -2.5 at any site
- IV. CCL reduced by 30% or more

- ❖ Radiolabelled Tec SPECT & intra-operative S. PTH sampling

Familial hypocalciuric hypercalcemia

- Mutation in CaSR in PTH gland n Kidney
- Usually asymptomatic
- Must be differentiated from Pr. hyperPTH as medical therapy or surgery not useful (*K)



© 2000 Elsevier Inc.

